On April 8, 2009, the FDA announced it had awarded Novartis a one-time priority review voucher (PRV) to use towards a future new drug application, for Coartem, a malaria drug. While the PRV was designed as an incentive to develop new drugs, Coartem was developed and put on the market outside the United States years before the PRV legislation was proposed.